Results 11 to 20 of about 329,666 (334)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling [PDF]

Diabetes, 2013
We investigated 1) the ability of purified glargine (GLA), metabolites 1 (M1) and 2 (M2), IGF-I, and NPH insulin to activate the insulin receptor (IR)-A and IR-B and IGF-I receptor (IGF-IR) in vitro; 2) plasma concentrations of GLA, M1, and M2 during long-term insulin therapy in type 2 diabetic patients; and 3) IR-A and IR-B activation in vitro induced
Joseph A M J L Janssen, Hannele Yki-Järvinen, Hannele Yki-Järvinen, Ronald Schmidt, Norbert Tennagels, Aimee J. Varewijck   +5 more
openaire   +4 more sources

Mouse Mutants Lacking the Type 2 IGF Receptor (IGF2R) Are Rescued from Perinatal Lethality inIgf2andIgf1rNull Backgrounds

Developmental Biology, 1996
The cation-dependent and cation-independent mannose 6-phosphate receptors (CD- and CI-MPRs) bind the phosphomannosyl recognition marker of lysosomal hydrolases, but in mammals the latter also interacts with insulin-like growth factor II (IGF-II). While IGF signaling is mediated by the type 1 IGF receptor (IGF1R), the type 2 receptor (IGF2R/CI-MPR ...
Marsha L. Davenport, Jonathan T. Eggenschwiler, A. Joseph D'Ercole, Peter Fisher, Argiris Efstratiadis, Thomas Ludwig   +5 more
openaire   +3 more sources

Purification of the Insulin-like growth factor II (IGF-II) receptor from an IGF-II-producing cell line, and generation of an antibody which both immunoprecipitates and blocks the type 2 IGF receptor

Biochemical and Biophysical Research Communications, 1986
18,54-SF cells, which secrete rat insulin-like growth factor II (rIGF-II), have abundant type 2 IGF receptors. We have purified the type 2 receptor from these cells by solubilization of crude membranes in Triton X-100, followed by chromatography on agarose-immobilized rIGF-II.
Hung Pham, D. Hodges, Phillip D.K. Lee, Ron G. Rosenfeld, David R. Powell   +4 more
openaire   +4 more sources

Insulin-like growth factor (IGF)-II- mediated fibrosis in pathogenic lung conditions.

PLoS ONE, 2019
Type 2 insulin-like growth factor (IGF-II) levels are increased in fibrosing lung diseases such as idiopathic pulmonary fibrosis (IPF) and scleroderma/systemic sclerosis-associated pulmonary fibrosis (SSc). Our goal was to investigate the contribution of
Sara M Garrett, Eileen Hsu, Justin M Thomas, Joseph M Pilewski, Carol Feghali-Bostwick   +4 more
doaj   +2 more sources

Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells

Frontiers in Physiology, 2014
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is one of the most lethal human diseases. PDAC is now the fourth leading cause of cancer mortality in both men and women and deaths due to PDAC are projected to increase
Enrique eRozengurt
doaj   +2 more sources

PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer

PPAR Research, 2009
It is now well established that the development and progression of a variety of human malignancies are associated with dysregulated activity of the insulin-like growth factor (IGF) system. In this regard, promising drugs have been developed to target the
A. Belfiore, M. Genua, R. Malaguarnera
doaj   +2 more sources

Cognitive disorder and dementia in type 2 diabetes mellitus

World Journal of Diabetes, 2022
Insulin, a key pleiotropic hormone, regulates metabolism through several signaling pathways in target tissues including skeletal muscle, liver, and brain.
G. Ortiz, M. Huerta, H. González-Usigli, E. D. Torres-Sánchez, Daniela L C Delgado-Lara, F. Pacheco-Moisés, M. Mireles-Ramírez, B. Torres-Mendoza, Roxana I Moreno-Cih, I. E. Velazquez-Brizuela   +9 more
semanticscholar   +1 more source

Novel Role of the IGF-1 Receptor in Endothelial Function and Repair: Studies in Endothelium-Targeted IGF-1 Receptor Transgenic Mice [PDF]

, 2012
We recently demonstrated that reducing IGF-1 receptor (IGF-1R) numbers in the endothelium enhances nitric oxide (NO) bioavailability and endothelial cell insulin sensitivity.
A. Abbas, A. Skromna, Booth, Bredt, Chen, Cubbon, D. J. Beech, De Meyts, Federici, Fulton, Gatenby, GUILLOT, H. Imrie, H. Viswambharan, J. Smith, Jiang, K. M. Channon, Kubota, Li, M. Gage, M. T. Kearney, N. Yuldasheva, Nakagawa, P. J. Grant, P. Sukumar, R. M. Cubbon, Razani, S. B. Wheatcroft, S. Galloway, S. T. Rashid, S. Xuan, Schleicher, Stegmayr, T. S. Futers, V. K. Gatenby, Vicent, Wheatcroft   +36 more
core   +1 more source

The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. [PDF]

PLoS ONE, 2011
A correlation between components of the insulin-like growth factor (IGF) system and endometrial cancer risk has been shown in recent studies. The antitumor action of vorinostat, a histone deacetylase inhibitor, involves changes in the expression of ...
Rive Sarfstein, Ilan Bruchim, Ami Fishman, Haim Werner   +3 more
doaj   +1 more source

Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy [PDF]

, 1992
The insulin like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptor has been detected in many cells and tissues. In the rat, there is a dramatic developmental regulation of IGF-II/M6P receptor expression, the receptor being high in fetal and ...
Eisenmenger, Wolfgang, Funk, B., Hansmann, A., Kessler, U., Kiess, W., Kolb, H. J.   +5 more
core   +1 more source